EDN1 and myeloid sarcoma: The detection of CSF ET-1 levels may allow to identify groups of ON patients potentially benefitting from treatment with ET-1 antagonists (e.g., bosentan) [6, 26] rather than from high doses of iv corticosteroids commonly used to treat acute visual exacerbation in MS.